[Correspondence] Revisiting quantitative PCR positivity thresholds to inform the development of shorter benznidazole regimens

We read with great interest the Article by James A Watson and colleagues published in The Lancet Microbe,1 who applied a hierarchical Bayesian model to individual patient data from the E1224 and BENDITA trials. This innovative pooled analysis showed that 4-week daily benznidazole regimens achieved cure rates approaching those of the 8-week standard—an important observation with implications for optimising future treatment strategies. However, the interpretation of the observation depends crucially on how quantitative PCR (qPCR) positivity is defined.